Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.36 |
| ▸ | VEGFA | P15692 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.34 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.34 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14810583 | 0.93 | MEN1 (0.37) | MAPTTP53HTTEGLN1ALDH1A1 | |
| SCHEMBL14810111 | 0.92 | MAPT (0.39) | MAPTTP53LMNAEGLN1VEGFA | |
| SCHEMBL14809783 | 0.92 | EGLN1 (0.36) | MAPTTP53LMNAHTTEGLN1 | |
| SCHEMBL14809836 | 0.91 | MAPT (0.36) | MAPTTP53LMNACYP3A4ALDH1A1 | |
| SCHEMBL16252239 | 0.90 | CYP3A4 (0.34) | EGLN1VEGFACYP3A4LIPG | |
| SCHEMBL14810135 | 0.90 | CYP3A4 (0.34) | EGLN1VEGFACYP3A4LIPG | |
| SCHEMBL14823828 | 0.89 | CYP3A4 (0.36) | CYP3A4LIPGALDH1A1KMT2AKDM4E | |
| SCHEMBL16252243 | 0.89 | CYP3A4 (0.36) | MAPTCYP3A4LIPGALDH1A1KMT2A | |
| SCHEMBL14810084 | 0.88 | CYP3A4 (0.36) | TP53LMNACYP3A4LIPGALDH1A1 | |
| SCHEMBL14809430 | 0.88 | KCNH2 (0.37) | MAPTTP53LMNAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757887-B1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV HEALTHCARE UK LTD (GB) | 2017-04-26 | — | — | EP | claimed |
| US-9012642-B2 | Pyrrolopyridinone compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-04-21 | — | — | US | claimed |
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2014-11-20 | — | — | US | claimed |
| EP-2757887-A1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV Healthcare UK Limited (GB) | 2014-07-30 | — | — | EP | claimed |
| WO-2013043553-A1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2013-03-28 | — | — | WO | claimed |
| EP-2757887-B1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV HEALTHCARE UK LTD (GB) | 2017-04-26 | — | — | EP | disclosed |
| EP-2757887-B1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV HEALTHCARE UK LTD (GB) | 2017-04-26 | — | — | EP | disclosed |
| US-9012642-B2 | Pyrrolopyridinone compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| US-9012642-B2 | Pyrrolopyridinone compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| US-9012642-B2 | Pyrrolopyridinone compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| EP-2757887-A1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV Healthcare UK Limited (GB) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013043553-A1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013043553-A1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | DHPS, PRNP, TYMP | MAPT 1289/4885TP53 1070/4885LMNA 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.